FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function

被引:15
作者
Ito, Takanori [1 ]
Kumada, Takashi [1 ]
Toyoda, Hidenori [1 ]
Tada, Toshifumi [1 ]
机构
[1] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Gifu 5038052, Japan
关键词
FIB-4; index; Noninvasive fibrosis marker; Prognosis; Hepatocellular carcinoma; Child-Pugh classification; CHRONIC HEPATITIS-B; SIMPLE NONINVASIVE INDEX; SIGNIFICANT FIBROSIS; SOFOSBUVIR; EPIDEMIOLOGY; LEDIPASVIR; ENTECAVIR; CIRRHOSIS; EFFICACY; PREDICT;
D O I
10.1007/s00432-015-1922-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the prognosis of hepatocellular carcinoma (HCC) patients with Child-Pugh (C-P) class A based on FIB-4 index, which is a liver fibrosis marker. A total of 915 HCC patients with C-P class A were investigated. We assessed the prognosis using FIB-4 index, and factors associated with survival rates were analyzed in these patients. When patients were categorized according to FIB-4 index as < 2.0 (n = 93), a parts per thousand yen2.0 and < 4.0 (n = 311), and a parts per thousand yen4.0 (n = 511), survival rates at 5 years were 70.5 % [95 % confidence interval (CI) 59.0-79.9], 56.4 % (95 % CI 50.1-62.5), and 47.1 % (95 % CI 42.2-52.1), respectively. Patients with FIB-4 index < 2.0 had a higher survival rate than the other groups (a parts per thousand yen4.0 vs a parts per thousand yen2.0 and < 4.0, p = 0.010; a parts per thousand yen2.0 and < 4.0 vs < 2.0, p = 0.028). We were able to predict prognosis in patients with C-P score 5 by FIB-4 index, but survival rate did not significantly differ in patients with C-P score 6. Multivariate analysis identified C-P score, FIB-4 index [a parts per thousand yen2.0 and < 4.0; hazard ratios (HRs) 1.638 (95 % CI 1.084-2.474); p = 0.019/a parts per thousand yen4.0; HR 1.828 (95 % CI 1.217-2.744); p = 0.004], Lens culinaris agglutinin-reactive alpha-fetoprotein, tumor size, number, vascular invasion, antiviral therapy, and hepatectomy as independent predictive factors for survival. The FIB-4 index is useful for assessing prognosis in HCC patients with C-P class A, especially those with C-P score 5.
引用
收藏
页码:1311 / 1319
页数:9
相关论文
共 31 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Reddy, K. Rajender ;
Nelson, David R. ;
Lawitz, Eric ;
Gordon, Stuart C. ;
Schiff, Eugene ;
Nahass, Ronald ;
Ghalib, Reem ;
Gitlin, Norman ;
Herring, Robert ;
Lalezari, Jacob ;
Younes, Ziad H. ;
Pockros, Paul J. ;
Di Bisceglie, Adrian M. ;
Arora, Sanjeev ;
Subramanian, G. Mani ;
Zhu, Yanni ;
Dvory-Sobol, Hadas ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
Kwo, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493
[3]  
[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
[4]   Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis [J].
Buster, Erik H. C. J. ;
Hansen, Bettina E. ;
Buti, Maria ;
Delwaide, Jean ;
Niederau, Claus ;
Michielsen, Peter P. ;
Flisiak, Robert ;
Zondervan, Pieter E. ;
Schalm, Solko W. ;
Janssen, Harry L. A. .
HEPATOLOGY, 2007, 46 (02) :388-394
[5]  
Clinical Practice Guidelines for Hepatocellular Carcinoma, 2009, HEPATOL RES, V2010, P2
[6]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[7]  
European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.jhep.2011.12.001, 10.1016/j.ejca.2011.12.021]
[8]   A prognostic model for predicting survival in cirrhosis with ascites [J].
Fernández-Esparrach, G ;
Sánchez-Fueyo, A ;
Ginès, P ;
Uriz, J ;
Quintó, L ;
Ventura, PJ ;
Cárdenas, A ;
Guevara, M ;
Sort, P ;
Jiménez, W ;
Bataller, R ;
Arroyo, V ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 34 (01) :46-52
[9]   PROGNOSTIC FACTORS OF HEPATOCELLULAR-CARCINOMA IN PATIENTS UNDERGOING HEPATIC RESECTION [J].
IZUMI, R ;
SHIMIZU, K ;
II, T ;
YAGI, M ;
MATSUI, O ;
NONOMURA, A ;
MIYAZAKI, I .
GASTROENTEROLOGY, 1994, 106 (03) :720-727
[10]   Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options [J].
Jacobson, Ira M. ;
Gordon, Stuart C. ;
Kowdley, Kris V. ;
Yoshida, Eric M. ;
Rodriguez-Torres, Maribel ;
Sulkowski, Mark S. ;
Shiffman, Mitchell L. ;
Lawitz, Eric ;
Everson, Gregory ;
Bennett, Michael ;
Schiff, Eugene ;
Al-Assi, M. Tarek ;
Subramanian, G. Mani ;
An, Di ;
Lin, Ming ;
McNally, John ;
Brainard, Diana ;
Symonds, William T. ;
McHutchison, John G. ;
Patel, Keyur ;
Feld, Jordan ;
Pianko, Stephen ;
Nelson, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1867-1877